Background: Recently, childhood obesity has become one of the most serious public health problems in the world. Gestational diabetes mellitus (GDM) is considered a risk factor for childhood overweight and obesity. The study aimed at investigating the relationship between maternal GDM and childhood obesity in children aged from 1 to 3 years. Methods: In this retrospective cohort study, 237 GDM and 296 non-GDM mothers and their offspring who were followed up by Family Medicine Clinics in Rize province of Turkey were assessed. World Health Organization (WHO) criteria were used for the diagnosis of maternal GDM. Crude and adjusted logistic regression models were calculated for the association of gestational diabetes and childhood overweight/obesity. Gender and age-specific percentile tables were used for the categorization of BMI. Results: Statistical analysis carried out with adjustment for potential confounders (mother's age, educational status, smoking status, BMI, gestational weight gain, children's gender, and gestational birth weight) provided results with an odds ratio of 2.99; 95% CI 1.14-7.94 and 7.77; 95% CI 1.92-31.37 for the impact of gestational diabetes on childhood overweight and obesity at 2 and 3 years of age, respectively. Conclusions: This study found evidence for maternal GDM to cause the risk of early childhood obesity. Therefore, proper intervention strategies are required for this high-risk population.
İntroduction: Standard treatment for hypothyroidism is replacement with synthetic Levothyroxine (LT4) sodium preparations. LT4 should be taken on an empty stomach at least 30 minutes before a meal, as maximal absorption occurs when taken on an empty stomach. Protein Pump Inhibitor (PPI), iron sulphate, calcium carbonate have been shown to reduce the absorption of LT4 when taken together with LT4. Therefore, patients receiving LT4 should be informed to take their drugs at least 4 hours before drugs that interact with thyroid hormone absorption. Objective: The aim of this study is to evaluate the correct use of levothyroxine drug, which is widely used in the society, in patients with hypothyroidism, to reveal the reasons for misuse, and to associate the number of drugs used by patients, types and chronic diseases. Material and method: Our study was conducted with a face-to-face questionnaire consisting of 18 questions in patients who applied to Recep Tayyip Erdoğan University Education and Research Hospital Endocrinology and Metabolic Diseases Polyclinic and Family Medicine outpatient clinic between 10-20 June 2020 and used LT4 due to any reason of hypothyroidism, and by obtaining patient consent. Results: 103 patients, 15 men and 88 women, participated in our study. 103 (100%) of the patients participating in our study took their medication in the morning and stored it in the right place. 94 of them (91.3%) took their medication regularly. 92 of them (89.3%) used their medicine at least 30 minutes before the meal. 60 of the patients (58.25%) used their medication correctly. 18 (41.9%) of the 43 people who used wrong medication were using PPI, 7 (16.3%) calcium carbonate, 5 (11.6%) ferrous sulfate. When compared in terms of correct use, a statistically significant difference (p <0.05) was found in patients with gender, age, presence of hypertension, presence of chronic disease, number of drugs used, ppi use, and calcium carbonate use. Conclusion: Our study highlights the insufficient knowledge about LT4 therapy among hypothyroid patients, the high prevalence of faulty applications, and the reasons for misapplication. These factors can lead to non-compliance and patient care not being optimal. It is important for physicians to inform patients about how to use the drug in terms of follow-up and treatment of the disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.